Systematic reviews and meta-analyses have become the cornerstone methodologies for integrating multi-source research data and enhancing the quality of evidence. Traditional meta-analyses often demonstrate limitations when handling multiple treatment options. Network meta-analysis (NMA) overcomes these limitations by constructing a network of evidence that encompasses various treatment options, allowing for the simultaneous comparison of both direct and indirect evidence across multiple treatment plans. This provides more comprehensive and precise support for clinical decision-making. This article comprehensively reviews the statistical principles of NMA, its three fundamental assumptions, and the statistical inference framework. It also critically analyzes the mainstream NMA software and packages currently available, such as R (including gemtc, netmeta, rjags, pcnetmeta), Stata (mvmeta, network), WinBUGS, SAS, ADDIS, and various online applications, highlighting their strengths, weaknesses, and suitable scenarios. This analysis provides researchers with a scientific and unified framework for conducting clinical studies and policy-making.
Accurately assessing the risk of bias is a critical challenge in network meta-analysis (NMA). By integrating direct and indirect evidence, NMA enables the comparison of multiple interventions, but its outcomes are often influenced by bias risks, particularly the propagation of bias within complex evidence networks. This paper systematically reviews commonly used bias risk assessment tools in NMA, highlighting their applications, limitations, and challenges across interventional trials, observational studies, diagnostic tests, and animal experiments. Addressing the issues of tool misapplication, mixed usage, and the lack of comprehensive tools for overall bias assessment in NMA, we propose strategies such as simplifying tool operation, enhancing usability, and standardizing evaluation processes. Furthermore, advancements in artificial intelligence (AI) and large language models (LLMs) offer promising opportunities to streamline bias risk assessments and reduce human interference. The development of specialized tools and the integration of intelligent technologies will enhance the rigor and reliability of NMA studies, providing robust evidence to support medical research and clinical decision-making.